阿法骨化醇与活力钙治疗绝经后骨质疏松症各128例的比较

Alfacalcidol(128 patients) vs Huoligai(128 patients) in treatment of postmenopausal osteoporosis

目的 :观察阿法骨化醇治疗绝经后骨质疏松症的疗效。方法 :绝经后骨质疏松症病人 2 5 6例 ,分成 2组 ,阿法骨化醇组 12 8例 ,年龄 ( 5 7±s7)a ,口服阿法骨化醇片剂 0 .5 μg·d- 1;活力钙组 12 8例 ,年龄 ( 5 6± 7)a ,给予活力钙片 2 0 0mg ,po ,qid ,疗程均为 6mo。观察病人用药后疼痛改善情况 ,计算有效率 ,并测定阿法骨化醇组用药前后骨矿含量和骨代谢生化指标。结果 :阿法骨化醇组总有效率为96.1%,活力钙组总有效率为 69.2 %(P <0 .0 1)。用药 6mo后 ,阿法骨化醇组病人血骨钙素、骨碱性磷酸酶、Ⅰ型前胶原羧基肽均上升 ,尿吡啶酚下降 ,与治疗前相比有非常显著意义 (P <0 .0 1)。骨密度无明显改变。结论 :阿法骨化醇治疗绝经后骨质疏松症具有改善症状、降低骨转换率、纠正骨量丢失的作用。

AIM: To observe the clinical effects of alfacalcidol in the treatment of postmenopausal osteoporosis. METHODS: Two hundred and fifty-six patients(age(57±s7)a) were divided into two groups. Alfacalcidol group of 128 patients (age(56±7)a ) received alfacalcidol 0.5 μg, po, qd for 6 mo. Huoligai group of 128 patients received Huoligai 200 mg, po, qid for 6mo, too. They were followed up and their pain changes before and after oral adminstrating medicine were observed. Bone biochemical determinations and bone mineral density (BMD) were also measured in alfacalcidol group. RESULTS: The total effective rates of alfacalcidol group and Huoligai group were 96.1% and 69.2%(P< 0.01). In alfacalcidol group, after 6 mo taking medicine, bone formation makers significantly elevated and bone absorption markers significantly decreased. BMD had no change. CONCLUSIONS: Alfacalcidol can alleviate symptoms, decrease bone turnover rate and redress loss of bone density in postmenopausal osteoporosis.